Hari M - Search Results

1

Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel.

Hari M, Yang H, Zeng C, Canizales M, Cabral F. Hari M, et al. Cell Motil Cytoskeleton. 2003 Sep;56(1):45-56. doi: 10.1002/cm.10132. Cell Motil Cytoskeleton. 2003. PMID: 12905530

2

Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine.

Hari M, Wang Y, Veeraraghavan S, Cabral F. Hari M, et al. Mol Cancer Ther. 2003 Jul;2(7):597-605. Mol Cancer Ther. 2003. PMID: 12883031

3

Paclitaxel resistance by random mutagenesis of α-tubulin.

Yin S, Zeng C, Hari M, Cabral F. Yin S, et al. Among authors: hari m. Cytoskeleton (Hoboken). 2013 Dec;70(12):849-62. doi: 10.1002/cm.21154. Epub 2013 Nov 15. Cytoskeleton (Hoboken). 2013. PMID: 24155014

4

Random mutagenesis of β-tubulin defines a set of dispersed mutations that confer paclitaxel resistance.

Yin S, Zeng C, Hari M, Cabral F. Yin S, et al. Among authors: hari m. Pharm Res. 2012 Nov;29(11):2994-3006. doi: 10.1007/s11095-012-0794-5. Epub 2012 Jun 6. Pharm Res. 2012. PMID: 22669706

5

Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.

Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM. Hari M, et al. Mol Cancer Ther. 2006 Feb;5(2):270-8. doi: 10.1158/1535-7163.MCT-05-0190. Mol Cancer Ther. 2006. PMID: 16505100

6

Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.

Nunes M, Kaplan J, Wooters J, Hari M, Minnick AA Jr, May MK, Shi C, Musto S, Beyer C, Krishnamurthy G, Qiu Y, Loganzo F, Ayral-Kaloustian S, Zask A, Greenberger LM. Nunes M, et al. Among authors: hari m. Biochemistry. 2005 May 10;44(18):6844-57. doi: 10.1021/bi0474766. Biochemistry. 2005. PMID: 15865430

7

Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin.

Loganzo F, Hari M, Annable T, Tan X, Morilla DB, Musto S, Zask A, Kaplan J, Minnick AA Jr, May MK, Ayral-Kaloustian S, Poruchynsky MS, Fojo T, Greenberger LM. Loganzo F, et al. Among authors: hari m. Mol Cancer Ther. 2004 Oct;3(10):1319-27. Mol Cancer Ther. 2004. PMID: 15486199

8

HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.

Loganzo F, Discafani CM, Annable T, Beyer C, Musto S, Hari M, Tan X, Hardy C, Hernandez R, Baxter M, Singanallore T, Khafizova G, Poruchynsky MS, Fojo T, Nieman JA, Ayral-Kaloustian S, Zask A, Andersen RJ, Greenberger LM. Loganzo F, et al. Among authors: hari m. Cancer Res. 2003 Apr 15;63(8):1838-45. Cancer Res. 2003. PMID: 12702571

9

Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.

Sampath D, Greenberger LM, Beyer C, Hari M, Liu H, Baxter M, Yang S, Rios C, Discafani C. Sampath D, et al. Among authors: hari m. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3459-69. doi: 10.1158/1078-0432.CCR-05-2349. Clin Cancer Res. 2006. PMID: 16740771

10

Correction to: Community‑acquired hypokalemia in elderly patients: related factors and clinical outcomes.

Bardak S, Turgutalp K, Koyuncu MB, Harı M, Helvacı I, Ovla D, Horoz M, Demir S, Kıykım A. Bardak S, et al. Among authors: hari m. Int Urol Nephrol. 2022 Mar 31. doi: 10.1007/s11255-022-03197-2. Online ahead of print. Int Urol Nephrol. 2022. PMID: 35357623 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results